Silverarc Capital Management, LLC Jounce Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$2.8 - $7.67 $695,371 - $1.9 Million	-248,347 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $15,133 - $21,503	2,518 Added 1.02%	248,347 $1.69 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $264,989 - $359,282	37,270 Added 17.87%	245,829 $2.05 Million
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $212,108 - $367,402	-42,085 Reduced 16.79%	208,559 $1.55 Million
Q2 2021 Aug 16, 2021	SELL	$6.58 - $10.66 $653,762 - $1.06 Million	-99,356 Reduced 28.39%	250,644 $1.7 Million
Q1 2021 May 18, 2021	SELL	$6.73 - $13.87 $381,355 - $785,943	-56,665 Reduced 13.93%	350,000 $3.6 Million
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $2.59 Million - $4.2 Million	406,665 New	406,665 $2.85 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.